NEW YORK (AP) -- Shares of cancer test maker Genomic Health Inc. plunged Thursday after the company reported disappointing sales of its Oncotype DX cancer test. THE SPARK: The Redwood City, Calif., ...
We reiterate our Neutral recommendation on Genomic Health (GHDX) following its fourth-quarter 2011 results though the performance missed the Zacks Consensus Estimates on both fronts - revenue and ...
Madison, Wisconsin-based Exact Sciences develops cancer screening and diagnostic tests. Its portfolio includes established brands like Cologuard and Oncotype Dx, alongside the Cancerguard test for ...
Thermo Fisher Scientific TMO recently received approval from the Food and Drug Administration (“FDA”) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be ...
Investor's Business Daily on MSN
Exact Sciences Catapults, Breaking Out, On Rumored Abbott Laboratories
Exact Sciences stock catapulted Wednesday amid rumors Abbott Laboratories is nearing a deal to buy the cancer-finding ...
Pertuzumab/Docetaxel/Carboplatin/Trastuzumab Regimen in Human Epidermal Growth Factor Receptor 2–Positive Early, Locally Advanced, and Oligometastatic Breast Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback